OptiBiotix Health said subsidiary ProBiotix Health had appointed EIWA Trading as the exclusive distributor of its cholesterol and blood pressure-reducing probiotic product in Japan.
The agreement granted EIWA the exclusive rights to import, market and distribute the s-called LPLDL product in Japan for a period of three years.
Market exclusivity was linked to increasing minimum annual volumes in order to maximise the financial return for both parties, which OptiBiotix said provided some surety of income.
'This deal provides OptiBiotix market access in Japan, the main national market for probiotics within the largest region for probiotics in the world,' chief executive Stephen O'Hara said.
'We have chosen EIWA as they are a well-known and respected provider of probiotics to the Japanese food, dairy and supplement industries, creating the potential to extend the use of LPLDL beyond supplements in a major international market.'